184 related articles for article (PubMed ID: 38300970)
1. Small Molecule Antagonists of the DNA Repair ERCC1/XPA Protein-Protein Interaction.
Obermann R; Yemane B; Jarvis C; Franco FM; Kyriukha Y; Nolan W; Gohara B; Krezel AM; Wildman SA; Janetka JW
ChemMedChem; 2024 Apr; 19(8):e202300648. PubMed ID: 38300970
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA.
Tsodikov OV; Ivanov D; Orelli B; Staresincic L; Shoshani I; Oberman R; Schärer OD; Wagner G; Ellenberger T
EMBO J; 2007 Nov; 26(22):4768-76. PubMed ID: 17948053
[TBL] [Abstract][Full Text] [Related]
3. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
Gentile F; Tuszynski JA; Barakat KH
J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
[TBL] [Abstract][Full Text] [Related]
4. The XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways.
Orelli B; McClendon TB; Tsodikov OV; Ellenberger T; Niedernhofer LJ; Schärer OD
J Biol Chem; 2010 Feb; 285(6):3705-3712. PubMed ID: 19940136
[TBL] [Abstract][Full Text] [Related]
5. Conformational determinants for the recruitment of ERCC1 by XPA in the nucleotide excision repair (NER) Pathway: structure and dynamics of the XPA binding motif.
Fadda E
Biophys J; 2013 Jun; 104(11):2503-11. PubMed ID: 23746523
[TBL] [Abstract][Full Text] [Related]
6. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
[TBL] [Abstract][Full Text] [Related]
7. DNA repair gets physical: mapping an XPA-binding site on ERCC1.
Croteau DL; Peng Y; Van Houten B
DNA Repair (Amst); 2008 May; 7(5):819-26. PubMed ID: 18343204
[TBL] [Abstract][Full Text] [Related]
8. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin.
Rosenberg E; Taher MM; Kuemmerle NB; Farnsworth J; Valerie K
Cancer Res; 2001 Jan; 61(2):764-70. PubMed ID: 11212280
[TBL] [Abstract][Full Text] [Related]
9. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
[TBL] [Abstract][Full Text] [Related]
10. Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach.
Barakat KH; Torin Huzil J; Luchko T; Jordheim L; Dumontet C; Tuszynski J
J Mol Graph Model; 2009 Sep; 28(2):113-30. PubMed ID: 19473860
[TBL] [Abstract][Full Text] [Related]
11. ERCC1-XPF targeting to psoralen-DNA crosslinks depends on XPA and FANCD2.
Sabatella M; Pines A; Slyskova J; Vermeulen W; Lans H
Cell Mol Life Sci; 2020 May; 77(10):2005-2016. PubMed ID: 31392348
[TBL] [Abstract][Full Text] [Related]
12. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.
Cummings M; Higginbottom K; McGurk CJ; Wong OG; Köberle B; Oliver RT; Masters JR
Biochem Pharmacol; 2006 Jul; 72(2):166-75. PubMed ID: 16756962
[TBL] [Abstract][Full Text] [Related]
13. Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction.
Barakat KH; Jordheim LP; Perez-Pineiro R; Wishart D; Dumontet C; Tuszynski JA
PLoS One; 2012; 7(12):e51329. PubMed ID: 23272099
[TBL] [Abstract][Full Text] [Related]
14. Regulation of DNA repair gene expression in human cancer cell lines.
McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
[TBL] [Abstract][Full Text] [Related]
15. TGF beta promotes repair of bulky DNA damage through increased ERCC1/XPF and ERCC1/XPA interaction.
Zheng H; Jarvis IWH; Bottai M; Dreij K; Stenius U
Carcinogenesis; 2019 Jun; 40(4):580-591. PubMed ID: 30418489
[TBL] [Abstract][Full Text] [Related]
16. ERCC1, XPF and XPA-locoregional differences and prognostic value of DNA repair protein expression in patients with head and neck squamous cell carcinoma.
Prochnow S; Wilczak W; Bosch V; Clauditz TS; Muenscher A
Clin Oral Investig; 2019 Aug; 23(8):3319-3329. PubMed ID: 30498981
[TBL] [Abstract][Full Text] [Related]
17. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours.
Köberle B; Masters JR; Hartley JA; Wood RD
Curr Biol; 1999 Mar; 9(5):273-6. PubMed ID: 10074455
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of damage-specific DNA binding of XPA by interaction with the ERCC1 DNA repair protein.
Nagai A; Saijo M; Kuraoka I; Matsuda T; Kodo N; Nakatsu Y; Mimaki T; Mino M; Biggerstaff M; Wood RD
Biochem Biophys Res Commun; 1995 Jun; 211(3):960-6. PubMed ID: 7598728
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins.
Jiang H; Yang LY
Cancer Res; 1999 Sep; 59(18):4529-34. PubMed ID: 10493501
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
